Terns Pharmaceuticals, Inc. (TERN)
NASDAQ: TERN · Real-Time Price · USD
7.77
+0.27 (3.60%)
At close: Oct 24, 2025, 4:00 PM EDT
7.92
+0.15 (1.93%)
After-hours: Oct 24, 2025, 7:23 PM EDT
Terns Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts that cover Terns Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $13.99, which forecasts a 80.05% increase in the stock price over the next year. The lowest target is $7.44 and the highest is $20.
Price Target: $13.99 (+80.05%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Terns Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Maintains $20 → $15 | Buy | Maintains | $20 → $15 | +93.05% | Oct 23, 2025 |
| Barclays | Barclays | Buy Maintains $15 → $14 | Buy | Maintains | $15 → $14 | +80.18% | Oct 22, 2025 |
| Truist Securities | Truist Securities | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +157.40% | Oct 15, 2025 |
| Barclays | Barclays | Buy Initiates $15 | Buy | Initiates | $15 | +93.05% | Sep 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Initiates $7.44 | Hold | Initiates | $7.44 | -4.25% | Sep 4, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.15
from -1.12
EPS Next Year
-1.37
from -1.15
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.11 | -1.19 | |||
| Avg | -1.15 | -1.37 | |||
| Low | -1.23 | -1.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.